Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-222904
| Line item | THREE MONTHS ENDEDMARCH 31, 2026 | THREE MONTHS ENDEDMARCH 31, 2025 |
|---|---|---|
| Lease liability | (108) | (136) |
| Net cash used in operating activities | (18,037) | (8,616) |
| Cash Flows from Investing Activities: | ||
| Purchase of fixed assets | (675) | (3) |
| Net cash used in investing activities | (675) | (3) |
| Cash Flows from Financing Activities: | ||
| Proceeds from option exercises | 28 | 246 |
| Proceeds from issuance of common stock in public offering, net of issuance costs | 93,787 | — |
Item 1. Financial Statements.
FAQ
- What is Candel Therapeutics, Inc.'s capex?
- Candel Therapeutics, Inc. (CADL) reported capex of $675K in Q1 2026.
- How has Candel Therapeutics, Inc.'s capex changed year-over-year?
- Candel Therapeutics, Inc.'s capex increased by 22400.0% year-over-year, from $3K to $675K.
- What is the long-term trend for Candel Therapeutics, Inc.'s capex?
- Over 4 years (2021 to 2025), Candel Therapeutics, Inc.'s capex has grown at a -24.8% compound annual growth rate (CAGR), from $1.84M to $587K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Candel Therapeutics, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude